

Sanofi supports supply of Japanese Encephalitis vaccine for Australia

Sydney – Friday 11 March 2022 – Sanofi is playing a major role in supporting the health of Australians facing recent outbreaks of Japanese Encephalitis across the country.

Country Medical Lead for Sanofi Australia and New Zealand, Dr Iris Depaz, said vaccines had already started arriving in areas of most need.

“As one of the largest manufacturers of vaccines in the world, Sanofi is well positioned to supply Australia with additional doses at short notice,” Dr Depaz said.

“Initial doses of our vaccine have already been distributed in Australia and we are mobilising our global supply chain to support the delivery of many more.

“Vaccines offer the main protection against Japanese Encephalitis, which can only be transmitted to humans via mosquitoes that have recently bitten infected pigs or wading birds. Most infections are mild or without symptoms, but approximately 1 in 250 infections result in severe clinical illness. The case-fatality rate can be as high as 30% among those with disease symptoms.

“While Sanofi’s vaccine is normally used for Australians travelling overseas to endemic areas, we are well prepared to support Australia’s need for more vaccines with doses already manufactured being prepared for shipping into the country. This leverages our Global Supply Chain footprint, in particular across Asia Pacific, to achieve the best possible timeline.”

Sanofi expects to mobilise more than 100,000 doses for Australia. The vaccines will then be distributed to the affected areas in accordance with the Government vaccination plans.

Australians who are concerned about Japanese Encephalitis or are planning a trip overseas to an endemic area should speak with their healthcare professional for further information.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting

Media Release
Australia



sustainability and social responsibility at the center of our ambitions. Sanofi is listed on Euronext: SAN and NASDAQ: SNY

Media Contacts

Ben Seal, Sanofi Australia and New Zealand, 0422 003 068

Ben.Seal@sanofi.com

© Sanofi Australia and New Zealand. Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113 First issued March 2022.